Drug Profile
Research programme: neurodegenerative disorders therapeutics - Knopp
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Knopp Neurosciences
- Class
- Mechanism of Action Free radical inhibitors; Mitochondrial permeability transition pore inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 18 Nov 2008 Early research in Neurodegenerative disorders in USA (unspecified route)